Company Overview
Retractable Technologies, Inc. operates within the healthcare sector specifically focusing on the medical instruments and supplies industry, where it designs, develops, manufactures, and markets safety syringes and other safety medical products for professionals in the United States, North America, South America, and international markets. The company's primary product offerings include VanishPoint insulin syringes alongside tuberculin and insulin devices, catering to the critical need for safety mechanisms in medical administration. This entity maintains a workforce of 221 employees, supporting its operations across its global footprint while managing a total market capitalization of $20.06M. The combination of a market cap at $20.06M and annual revenue of $37.90M indicates that the company is a small-cap enterprise with a revenue base that significantly exceeds its current equity valuation, suggesting a distinct position in the market where asset backing and revenue generation diverge from the traditional equity market pricing models often seen in larger corporations.
Financial Health
The company reported a trailing twelve-month revenue of $37.90M, yet it recorded a net income of $-6,676,863 and an EBITDA of $-13,174,357, highlighting a substantial gap between top-line generation and bottom-line profitability that reveals a heavy cost structure or significant non-operating expenses eroding earnings. This negative net income relative to revenue suggests that for every dollar generated, the company is currently losing money after all expenses are accounted for, while the negative EBITDA further underscores operating losses before financing and non-cash items. The free cash flow stands at $-2,833,449, which indicates a consumption of cash rather than generation, implying limited immediate financial flexibility for capital expenditures or debt repayment without external financing. Margin analysis shows a gross margin of -2.4%, an operating margin of -36.2%, and a profit margin of -17.0%, where the negative gross margin suggests costs of goods sold are exceeding revenue, and the wider negative operating and profit margins reflect significant overhead burdens and loss-making operations. In terms of leverage, the company holds $33.95M in cash against $982,707 in debt, resulting in a debt-to-equity ratio of 1.28, which presents a balance sheet that appears conservative regarding absolute debt levels despite the negative equity implied by losses. The current ratio is 6.66, a figure that indicates strong short-term liquidity and an ability to cover current liabilities more than six times over with available assets. Finally, the return on equity is -8.0% and the return on assets is -8.5%, metrics that reveal that management is currently unable to generate positive returns on the capital invested or the assets utilized to operate the business.
Valuation Assessment
The trailing P/E ratio and forward P/E ratio are both listed as N/A, which implies that because the company is not currently profitable, traditional earnings-based valuation multiples cannot be calculated, removing any direct comparison to historical earnings growth trajectories. The price-to-book ratio is 0.26, a figure that indicates the market values the company at a fraction of its book value, suggesting a significant discount relative to the net asset value recorded on the balance sheet. Alternative valuation metrics such as the price-to-sales ratio of 0.53 and an EV/EBITDA of 0.96 provide context where the company trades at less than half of its annual sales and less than a full multiple of its earnings before interest, taxes, depreciation, and amortization, which are metrics often used for unprofitable or asset-heavy firms. The stock's 52-week trading range spans from a low of $0.62 to a high of $1.14, and given the current market conditions and historical volatility, the price position relative to this range fluctuates within this specific band without crossing into new highs or lows. The beta value is 1.32, which explains that the stock price volatility is 32% higher than the broader market, indicating that the share price moves with greater intensity than the general market index during periods of rising or falling equity prices.
Growth & Income
The revenue growth year-over-year is -2.5%, while earnings growth is N/A due to the lack of profitability, meaning there is no earnings trajectory to compare against revenue changes, but the revenue contraction indicates a shrinking top line. Since the company does not pay dividends, the dividend yield is N/A and the payout ratio is 0.0%, which means the company does not distribute cash to shareholders and instead retains any potential earnings, though in this instance, it is retaining losses. As a non-dividend payer, the company reinvests its resources into operations or growth initiatives rather than providing income to investors, a strategy typical for small-cap firms seeking expansion but currently constrained by profitability issues. The overall growth and income profile for Retractable Technologies, Inc. is characterized by negative revenue momentum, an absence of dividend income, and a valuation based on sales and assets rather than earnings power or cash flow generation.